Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asuptegravir
- Development stage
- Phase 2
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Asuptegravir (also known as ACC017 or AK-183) is an investigational, once-daily, next-generation HIV-1 integrase strand transfer inhibitor (INSTI) developed by Jiangsu Aidea Pharmaceutical. It is designed to block the integration of viral DNA into the host genome by chelating divalent metal ions within the integrase catalytic site. Asuptegravir has demonstrated potent antiviral activity against wild-type HIV-1 as well as a panel of drug-resistant strains in preclinical and early clinical studies. It is being evaluated both as a monotherapy and as part of a triple fixed-dose combination (FDC) tablet (ADC118) containing asuptegravir, emtricitabine, and tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection.
- Other names
- ASU
02
Targets
Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on asuptegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asuptegravir.